Positive Results for the SOLARIS Phase 3 Trial of Olanzapine

The Teva and Medincell companies reported positive efficacy results for the phase 3 SOLARIS trial, evaluating the antipsychotic TEV-'749 (olanzapine/mdc-TJK) in adults with schizophrenia. The study met its primary endpoint by achieving significant reductions in PANSS scores, measuring the severity of schizophrenia symptoms, compared to placebo.

The drug TEV-'749 is well tolerated, showing no signs of post-injection delirium/sedation syndrome (PDSS). Medincell's SteadyTeq™ technology, which provides controlled release of the widely prescribed antipsychotic olanzapine, was used in the development of this injectable formulation. Preliminary results also indicate significant improvement on other secondary endpoints, with no occurrence of PDSS reported to date.

These encouraging results confirm the potential of TEV-'749 as a long-acting treatment, providing a new option for the management of schizophrenia without the risks associated with intramuscular olanzapine. Further efficacy and safety results are expected at future conferences, with continued monitoring planned in the second phase of the SOLARIS study.